Medmira....der Knaller...TIPP 2008 - 500 Beiträge pro Seite
eröffnet am 16.07.08 19:10:31 von
neuester Beitrag 22.04.09 23:38:47 von
neuester Beitrag 22.04.09 23:38:47 von
Beiträge: 70
ID: 1.142.917
ID: 1.142.917
Aufrufe heute: 0
Gesamt: 16.431
Gesamt: 16.431
Aktive User: 0
ISIN: CA58501R1029 · WKN: 932414 · Symbol: 47M
0,0595
EUR
0,00 %
0,0000 EUR
Letzter Kurs 31.05.24 Tradegate
Neuigkeiten
| Titel |
|---|
01.05.24 · IRW Press |
01.05.24 · IRW Press |
01.05.24 · Accesswire  |
02.04.24 · Accesswire |
14.03.24 · IRW Press |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,2554 | +9.943,20 | |
| 7,9600 | +151,90 | |
| 1,7630 | +89,37 | |
| 6,6800 | +67,42 | |
| 2,3900 | +32,04 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 4,3000 | -16,83 | |
| 9,6000 | -18,64 | |
| 2,1150 | -26,56 | |
| 2,0400 | -58,87 | |
| 0,8020 | -91,06 |
Feedback
So...
wollte mal zu neuen knaller eine thread eröffnen...
Medmira...
zur zeit noch günstig in frankfurt zu haben!!!
also dann last was hören...
wollte mal zu neuen knaller eine thread eröffnen...
Medmira...
zur zeit noch günstig in frankfurt zu haben!!!
also dann last was hören...
Last TradeLast Trade: 16 Jul 2008 12:55 ET
Price 0.330 Net
Change +0.220
Last
Bid Size 100 Volume 10,739,799
Last
Bid Price 0.325 Open 0.115
Last
Ask Price 0.330 High 0.400
Last
Ask Size 2 Low 0.115
Price 0.330 Net
Change +0.220
Last
Bid Size 100 Volume 10,739,799
Last
Bid Price 0.325 Open 0.115
Last
Ask Price 0.330 High 0.400
Last
Ask Size 2 Low 0.115
hier aus dem BB
volume for the day has been incredible. This news, in addition to FDA approvals and other subsequent announcements, only affirms the momentum building here.
If this release is like the last one, and we get a couple of news releases following in the next few days or weeks, then this little run today is nothing to what we could see.
Enjoy good longs!
smts
volume for the day has been incredible. This news, in addition to FDA approvals and other subsequent announcements, only affirms the momentum building here.
If this release is like the last one, and we get a couple of news releases following in the next few days or weeks, then this little run today is nothing to what we could see.
Enjoy good longs!
smts
...naja, wer lust aufn ´heißen ritt´ hat, ist HIER richtig - man
sollte sich VORHER nur mal die last 12 month anschauen....angefangen
in 11.2007
Antwort auf Beitrag Nr.: 34.523.123 von hbg55 am 16.07.08 19:22:57dann schau dir die NEWS an....
es gibt eigentlich nur eine richtung...
UP
es gibt eigentlich nur eine richtung...
UP
Trading Spotlight
aus dem BB
volume for the day has been incredible. This news, in addition to FDA approvals and other subsequent announcements, only affirms the momentum building here.
If this release is like the last one, and we get a couple of news releases following in the next few days or weeks, then this little run today is nothing to what we could see.
volume for the day has been incredible. This news, in addition to FDA approvals and other subsequent announcements, only affirms the momentum building here.
If this release is like the last one, and we get a couple of news releases following in the next few days or weeks, then this little run today is nothing to what we could see.
Antwort auf Beitrag Nr.: 34.523.177 von blntrader am 16.07.08 19:27:22.....hätts ja ´gerne´ als thr. - eröffner mal reinstellen
können, gellllllllll
anyhow, hab sie gelesen, weil ich wert schon länger beobachte
und frag mich was DIR da besonders gefällt
...naja, dann schaun wir mal, wohins noch geht
können, gellllllllll
anyhow, hab sie gelesen, weil ich wert schon länger beobachte
und frag mich was DIR da besonders gefällt
...naja, dann schaun wir mal, wohins noch geht
Antwort auf Beitrag Nr.: 34.523.295 von hbg55 am 16.07.08 19:40:03genau der erste teil...
Dieses Patent schützt die Kerninnovation hinter MedMira' s-völlig in den Handel gebrachte Linie der schnellen Tests.
was will man mehr?!?!
Dieses Patent schützt die Kerninnovation hinter MedMira' s-völlig in den Handel gebrachte Linie der schnellen Tests.
was will man mehr?!?!
Antwort auf Beitrag Nr.: 34.523.295 von hbg55 am 16.07.08 19:40:03ach so und beim einstellen der kompletten NEWS...hat mir der browser gesponnen...versuche es aber gleich nochmal...
hier die NEWS
US Patent for Rapid Test Method and Technology Platform Awarded to MedMira
7/16/2008 8:40:23 AM - Canada NewsWire
HALIFAX, Jul 16, 2008 (Canada NewsWire via COMTEX News Network) --
MedMira Inc., ("MedMira") (TSX Venture: MIR, NASDAQ: MMIRF), a developer and marketer of rapid diagnostics, announced today that it received a Notice of Allowance from the United States Patent and Trademark Office for its rapid flow-through test (RFT) methodology, the technology platform its rapid tests are built on.
This patent protects the core innovation behind MedMira's fully commercialized line of rapid tests. The test can be used as an aid to diagnose one or multiple diseases using one test device and a single drop of blood. The Company's rapid tests have performed exceptionally well in rigorous clinical trials, earning regulatory approvals in major international markets including the United States, Canada, China, India, and the European Union. In a recent study led by Dr. S. M. Owen and published in the May 2008 issue of the Journal of Clinical Microbiology, MedMira's rapid HIV had the highest sensitivity and specificity of the FDA approved rapid tests assessed in the study. Additional results in the same study demonstrated that MedMira's rapid HIV detected early infection better than the other rapid tests and closely matched the performance of much more complex enzyme tests. MedMira is now poised to capitalize on its intellectual property estate in North American and the European Union through its partnership development strategy and program.
"Being awarded this new US patent clearly reinforces MedMira's position as the owner of one of the two most recognizable rapid diagnostic technologies in the global marketplace. It further increases the overall value of our company and creates future revenue potential through the formation of strategic relationships with development and licensing partners, bringing new, advanced rapid tests to the global healthcare market," said Hermes Chan, President & CEO, MedMira Inc. "MedMira is well positioned to offer diagnostics developers a comprehensive solution as they create new rapid tests for global healthcare needs. Our RFT technology has unique capabilities and benefits that are unmatched by alternative technologies on the market today."
MedMira's RFT platform is uniquely capable of simultaneously detecting multiple disease markers in a single specimen in less than three minutes, a critical element for diagnostics developers creating streamlined products to meet the demands of increasingly under-resourced and under-funded healthcare systems. Building tests on MedMira's RFT technology enables multiple results using the same resources and materials required for a single diagnosis with rapid tests built on the alternative technology platform.
About MedMira
MedMira is a leading developer, manufacturer, and marketer of advanced rapid diagnostics. Built on the Company's patented rapid flow-through technology platform, MedMira's single and multiple rapid tests provide hospitals, labs, clinics and individuals around the world with reliable, diagnosis for diseases such as HIV and hepatitis C in just three minutes. The company's tests, which are sold under the Reveal(R), MiraWell(R), MiraCare(TM) and Multiplo(TM) brands in global markets, have achieved regulatory approvals in Canada, the United States, China, Russia, India, and the European Union. MedMira is an approved supplier to US Agency for International Development (USAID) and the Pan American Health Organization (PAHO).
In 2006, MedMira launched the Maple Biosciences division to develop and commercialize diagnostic instruments based on biosensor technology platforms. The new diagnostic solutions will enable routine laboratory tests to be performed in a matter of minutes, increasing automation, and streamlining the diagnosis of multiple conditions and diseases. Together MedMira and Maple Biosciences will be leading participants in the emerging fields of personalized medicine and molecular diagnostics. For more information visit www.maplebio.com.
MedMira's corporate offices, R&D, and manufacturing facilities are located in Halifax, Nova Scotia, Canada. For more information visit MedMira's website at www.medmira.com.
This news release contains forward-looking statements, which involve risk and uncertainties and reflect the company's current expectation regarding future events. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this statement.
%SEDAR: 00013053E
SOURCE: MedMira Inc.
Dr. James Smith, Investor Relations & Corporate Affairs, (902) 450-1588, ir@medmira.com
Copyright (C) 2008 CNW Group. All rights reserved.
US Patent for Rapid Test Method and Technology Platform Awarded to MedMira
7/16/2008 8:40:23 AM - Canada NewsWire
HALIFAX, Jul 16, 2008 (Canada NewsWire via COMTEX News Network) --
MedMira Inc., ("MedMira") (TSX Venture: MIR, NASDAQ: MMIRF), a developer and marketer of rapid diagnostics, announced today that it received a Notice of Allowance from the United States Patent and Trademark Office for its rapid flow-through test (RFT) methodology, the technology platform its rapid tests are built on.
This patent protects the core innovation behind MedMira's fully commercialized line of rapid tests. The test can be used as an aid to diagnose one or multiple diseases using one test device and a single drop of blood. The Company's rapid tests have performed exceptionally well in rigorous clinical trials, earning regulatory approvals in major international markets including the United States, Canada, China, India, and the European Union. In a recent study led by Dr. S. M. Owen and published in the May 2008 issue of the Journal of Clinical Microbiology, MedMira's rapid HIV had the highest sensitivity and specificity of the FDA approved rapid tests assessed in the study. Additional results in the same study demonstrated that MedMira's rapid HIV detected early infection better than the other rapid tests and closely matched the performance of much more complex enzyme tests. MedMira is now poised to capitalize on its intellectual property estate in North American and the European Union through its partnership development strategy and program.
"Being awarded this new US patent clearly reinforces MedMira's position as the owner of one of the two most recognizable rapid diagnostic technologies in the global marketplace. It further increases the overall value of our company and creates future revenue potential through the formation of strategic relationships with development and licensing partners, bringing new, advanced rapid tests to the global healthcare market," said Hermes Chan, President & CEO, MedMira Inc. "MedMira is well positioned to offer diagnostics developers a comprehensive solution as they create new rapid tests for global healthcare needs. Our RFT technology has unique capabilities and benefits that are unmatched by alternative technologies on the market today."
MedMira's RFT platform is uniquely capable of simultaneously detecting multiple disease markers in a single specimen in less than three minutes, a critical element for diagnostics developers creating streamlined products to meet the demands of increasingly under-resourced and under-funded healthcare systems. Building tests on MedMira's RFT technology enables multiple results using the same resources and materials required for a single diagnosis with rapid tests built on the alternative technology platform.
About MedMira
MedMira is a leading developer, manufacturer, and marketer of advanced rapid diagnostics. Built on the Company's patented rapid flow-through technology platform, MedMira's single and multiple rapid tests provide hospitals, labs, clinics and individuals around the world with reliable, diagnosis for diseases such as HIV and hepatitis C in just three minutes. The company's tests, which are sold under the Reveal(R), MiraWell(R), MiraCare(TM) and Multiplo(TM) brands in global markets, have achieved regulatory approvals in Canada, the United States, China, Russia, India, and the European Union. MedMira is an approved supplier to US Agency for International Development (USAID) and the Pan American Health Organization (PAHO).
In 2006, MedMira launched the Maple Biosciences division to develop and commercialize diagnostic instruments based on biosensor technology platforms. The new diagnostic solutions will enable routine laboratory tests to be performed in a matter of minutes, increasing automation, and streamlining the diagnosis of multiple conditions and diseases. Together MedMira and Maple Biosciences will be leading participants in the emerging fields of personalized medicine and molecular diagnostics. For more information visit www.maplebio.com.
MedMira's corporate offices, R&D, and manufacturing facilities are located in Halifax, Nova Scotia, Canada. For more information visit MedMira's website at www.medmira.com.
This news release contains forward-looking statements, which involve risk and uncertainties and reflect the company's current expectation regarding future events. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this statement.
%SEDAR: 00013053E
SOURCE: MedMira Inc.
Dr. James Smith, Investor Relations & Corporate Affairs, (902) 450-1588, ir@medmira.com
Copyright (C) 2008 CNW Group. All rights reserved.
Klärt mich mal auf, was das für ein toller Schnelltest sein soll.
Wäre es ein HIV- Test oder etwas vergleichbare, ok, wunderbar.
Schätze, das ist ein OTC-Wert ohne Hintergrund, aber nicht zu verachten, wenn das Ding einmal ans Laufen kommt.
Der Kurs wird nur weiterlaufen, wenn jeden Tag neue News kommen. Welche sollten das sein?
P.S.
Beachtet den letzten Abschnitt in der Meldung(yahoo), nicht von der TSX geprüft, steht dort!
Tendenziell Finger weg!
Letztendlich gab es damals bei der LAMP-Geschichte(erinnert sich jemand von den Alteingesessenen?) eine FDA-Zulassung, was viel wichtiger ist als eine Patentanmeldung(das kann jeder) bringt aber noch lange keine Umsätze.
Da sprang der Kurs mehrere 100%.
Aber hier nur wegen eines Patentes, was bringt das in den nächsten Jahren bitteschön?
Wäre es ein HIV- Test oder etwas vergleichbare, ok, wunderbar.
Schätze, das ist ein OTC-Wert ohne Hintergrund, aber nicht zu verachten, wenn das Ding einmal ans Laufen kommt.
Der Kurs wird nur weiterlaufen, wenn jeden Tag neue News kommen. Welche sollten das sein?
P.S.
Beachtet den letzten Abschnitt in der Meldung(yahoo), nicht von der TSX geprüft, steht dort!
Tendenziell Finger weg!
Letztendlich gab es damals bei der LAMP-Geschichte(erinnert sich jemand von den Alteingesessenen?) eine FDA-Zulassung, was viel wichtiger ist als eine Patentanmeldung(das kann jeder) bringt aber noch lange keine Umsätze.
Da sprang der Kurs mehrere 100%.
Aber hier nur wegen eines Patentes, was bringt das in den nächsten Jahren bitteschön?
Antwort auf Beitrag Nr.: 34.523.711 von MrRipley am 16.07.08 20:18:43Sorry, kein OTC. TSX natürlich. Verdienen die eigentlich gut?
Antwort auf Beitrag Nr.: 34.523.778 von MrRipley am 16.07.08 20:26:079 Monate Umsatz 1,2 Millionen
Stock option Plan
The Company has established a stock option plan for its shareholders, employees, officers,
directors and consultants. The options are exercisable into an equivalent of 2,521,980 common
shares at exercise prices ranging between $0.10 and $1.25. The options expire between the dates
of August 25, 2008 and October 10, 2012.
The Company has established a stock option plan for its shareholders, employees, officers,
directors and consultants. The options are exercisable into an equivalent of 2,521,980 common
shares at exercise prices ranging between $0.10 and $1.25. The options expire between the dates
of August 25, 2008 and October 10, 2012.
Antwort auf Beitrag Nr.: 34.524.155 von STOCK-HUNTER am 16.07.08 21:11:35Die paar Aktien stören auch nicht
Antwort auf Beitrag Nr.: 34.524.163 von STOCK-HUNTER am 16.07.08 21:12:26Für einen Jüngling bist Du ja schon kräftig am Rühren, wie man hier zu sagen pflegt.
Ich hoffe, das wird keine dieser Pusher- oder Bashertouren bzw. ID´s. Für Solides und Hintergrundwissen sind wir dagegen immer zu haben
Schönen Abend!
Ich hoffe, das wird keine dieser Pusher- oder Bashertouren bzw. ID´s.
Für Solides und Hintergrundwissen sind wir dagegen immer zu haben
Schönen Abend!
Antwort auf Beitrag Nr.: 34.524.210 von MrRipley am 16.07.08 21:17:46
Ich suche zumindest keinen Stress, sondern such Infos anstatt nur groß rumzuschreien.
Vielleicht vermisst dich das Sofa?
Ich suche zumindest keinen Stress, sondern such Infos anstatt nur groß rumzuschreien.
Vielleicht vermisst dich das Sofa?
Antwort auf Beitrag Nr.: 34.524.218 von MrRipley am 16.07.08 21:18:48Sehr solide
Not Found
The requested URL /gifs/chart_not_found.gif was not found on this server.
Not Found
The requested URL /gifs/chart_not_found.gif was not found on this server.
Antwort auf Beitrag Nr.: 34.523.177 von blntrader am 16.07.08 19:27:22
...wenns TRADER bist, vergißt du hofftl. nicht
gewinne mitzunehmen.......HEUTE noch !!!
...wenns TRADER bist, vergißt du hofftl. nicht
gewinne mitzunehmen.......HEUTE noch !!!
Antwort auf Beitrag Nr.: 34.524.218 von MrRipley am 16.07.08 21:18:48
also vorbösrlich baut sich da schon ordentlich was auf in can...
Bid
0.28 Ask
0.28
Bid Size
74,000 Ask Size
36,000
das wird heute wieder eine rallye...ziel 1,40
wer nicht dabei ist...selber schuld...
cu
Bid
0.28 Ask
0.28
Bid Size
74,000 Ask Size
36,000
das wird heute wieder eine rallye...ziel 1,40
wer nicht dabei ist...selber schuld...
cu
Bid
0.28 Ask
0.28
Bid Size
92,000 Ask Size
36,000
0.28 Ask
0.28
Bid Size
92,000 Ask Size
36,000
Antwort auf Beitrag Nr.: 34.529.552 von blntrader am 17.07.08 15:06:53Der Start könnte explosive werden.
BID .285 163500
ASK .285 87000
BID .285 163500
ASK .285 87000
Antwort auf Beitrag Nr.: 34.529.750 von STOCK-HUNTER am 17.07.08 15:27:08im ersten Schwung schon über die ,31.
Das war sehr gut.
Das war sehr gut.
Antwort auf Beitrag Nr.: 34.529.821 von STOCK-HUNTER am 17.07.08 15:33:00jetzt bin ich beruhigter.
Antwort auf Beitrag Nr.: 34.529.829 von STOCK-HUNTER am 17.07.08 15:33:27sauber würde ich sagen...
bin ja mal gespannt wann die das in frankfurt auch checken....
hast du was rt
bin ja mal gespannt wann die das in frankfurt auch checken....
hast du was rt
Die Kaufen ja wie die Blöden, könnt mir gut vorstellen das es einen ähnlichen Verlauf gibt wie im November, also bis 1,2CAD. Schaun wa mal, über der 200 Tagelinie sind wa schonmal, Widerstände sehe ich in nächster Zeit auch nich, zurücklehnen und genießen.
Antwort auf Beitrag Nr.: 34.529.852 von blntrader am 17.07.08 15:35:09FFM 
15:17:44 1.500 0,195
09:08:09 0 0,145
15:17:44 1.500 0,195
09:08:09 0 0,145
Antwort auf Beitrag Nr.: 34.529.885 von STOCK-HUNTER am 17.07.08 15:38:14na mal schauen wann die das hier in germany auch mal checken....
wahrscheinlich erst wann wir bein 1 euro stehen
wahrscheinlich erst wann wir bein 1 euro stehen
Antwort auf Beitrag Nr.: 34.529.905 von blntrader am 17.07.08 15:39:40Mir wurscht...allerdings gibts auch in Germany kaum Aktien. Finde es eh besser, wenn sich alles an einer Börse konzentriert
Antwort auf Beitrag Nr.: 34.529.871 von Bulle_und_Baer am 17.07.08 15:37:07selbst ,60 würde schon langen. Schaun mer mal, wie es sich weiter entwickelt.
61,8%
und nun auf der MA200- Mal sehen, was die hier zu sagen hat
und nun auf der MA200- Mal sehen, was die hier zu sagen hat
Antwort auf Beitrag Nr.: 34.529.946 von STOCK-HUNTER am 17.07.08 15:42:48bekomme keine zahlen von advfn...
mein browser hängt sich immer auf...
kannst du nicht hier einen rt chart einstellen???
mein browser hängt sich immer auf...
kannst du nicht hier einen rt chart einstellen???
300k Paket über SMA 200, die sollte aber auch halten, also unter 0,29CAD oder eröffnung 0,285CAD werd ich stutzig...
Antwort auf Beitrag Nr.: 34.529.998 von Bulle_und_Baer am 17.07.08 15:46:44ja, ist ein kampf gegen dir Bären
Antwort auf Beitrag Nr.: 34.530.012 von STOCK-HUNTER am 17.07.08 15:47:42super danke...
Antwort auf Beitrag Nr.: 34.530.012 von STOCK-HUNTER am 17.07.08 15:47:42jetzt sollte dann mind. die ,31 - ,315 geholt werden
Antwort auf Beitrag Nr.: 34.530.040 von STOCK-HUNTER am 17.07.08 15:49:14ist das ein Kampf
die 31 jetz noch weg, dann ist gut. Aber das sollte auch in einem Schwung passieren. Sonst füllen se immer wieder nach
die 31 jetz noch weg, dann ist gut. Aber das sollte auch in einem Schwung passieren. Sonst füllen se immer wieder nach
Antwort auf Beitrag Nr.: 34.530.176 von STOCK-HUNTER am 17.07.08 16:00:02wie???
jetzt wird hier mit kleinem volumen der sp gedrückt oder was?
jetzt wird hier mit kleinem volumen der sp gedrückt oder was?
ADVFN hat mal wieder ne Macke, wa
Antwort auf Beitrag Nr.: 34.530.411 von Bulle_und_Baer am 17.07.08 16:18:13sieht so aus...der chart kann ja wohl auch gerade nicht stimmen....
Antwort auf Beitrag Nr.: 34.530.411 von Bulle_und_Baer am 17.07.08 16:18:13ja, der stimmt nicht.
Bin raus. Viel Glück noch
Bin raus. Viel Glück noch
MedMira Announces Settlement of Debt
Tuesday October 21, 3:30 pm ET
HALIFAX, Oct. 21 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR, NASDAQ: MMIRF) a developer and marketer of rapid diagnostics, announced today that it has reached an agreement with debt holders to settle a total of $ 324,918.00 owing for debts to the Company through the issuance of 3,398,724 common shares. The Company will issue common shares at a price of $0.0956 per share calculated on the previous 10 day volume weighted average price. This agreement is subject to the approval of the TSX Venture Exchange. Shares issued under this agreement will be subject to mandatory four month hold period.
About MedMira
MedMira is a leading developer and manufacturer of flow-through rapid diagnostics. The company's tests provide hospitals, labs, clinics and individuals with reliable, rapid diagnosis for diseases such as HIV and hepatitis C in just three minutes. The company's tests are sold under the Reveal(R), MiraWell(R), MiraCare(TM) and Multiplo(TM) brands in global markets. MedMira's rapid HIV test is the only one in the world to achieve regulatory approvals in Canada, the United States, China and the European Union. MedMira's corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada. For more information visit MedMira's website at www.medmira.com.
This news release contains forward-looking statements, which involve risk and uncertainties and reflect the company's current expectation regarding future events. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this statement.
For further information
Dr. James Smith, Investor Relations & Corporate Affairs, (902) 450-1588, ir@medmira.com
Andrea Young, Corporate Communications, (902) 450-1588, media@medmira.com
Source: MedMira Inc.
.......NEUE wege sind gefragt - gelingts MIR hiermit jetzt trotz der globalen finanzkrise aus der schuldenfalle zu kommen
Antwort auf Beitrag Nr.: 35.670.778 von hbg55 am 23.10.08 09:17:08
MedMira Strengthens US Patent Protection with New Filings and Continued Examination
Tuesday October 21, 9:15 am ET
HALIFAX, Oct. 21 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR, NASDAQ: MMIRF), a developer and marketer of rapid diagnostics, announced today that it is broadening its US patent portfolio with new filings related to the Company's rapid flow-through technology, the core innovation behind its rapid diagnostics. In order to strengthen its overall IP position, the Company has also filed for continued examination on its original US patent application that was allowed in July 2008.
ADVERTISEMENT
"We believe that our technology is one of our Company's most valuable assets and as such we are taking further steps to strengthen the IP around it, as we move forward with licensing and partnership opportunities. Additional IP was identified during our review and analysis of our rapid flow-through technology and we are now working with our external team to prepare and file patent applications to protect it," said Dr. Neeraj Vats, VP of Technology & Intellectual Property, MedMira Inc. "We will also be filing a Request for Continued Examination in order to strengthen our original US patent application, which received a Notice of Allowance from the USPTO earlier this year."
About MedMira
MedMira is a leading developer and manufacturer of flow-through rapid diagnostics. The company's tests provide hospitals, labs, clinics and individuals with reliable, rapid diagnosis for diseases such as HIV and hepatitis C in just three minutes. The company's tests are sold under the Reveal(R), MiraWell(R), MiraCare(TM) and Multiplo(TM) brands in global markets. MedMira's rapid HIV test is the only one in the world to achieve regulatory approvals in Canada, the United States, China and the European Union. MedMira's corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada. For more information visit MedMira's website at www.medmira.com.
This news release contains forward-looking statements, which involve risk and uncertainties and reflect the company's current expectation regarding future events. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this statement.
For further information
Dr. James Smith, Investor Relations & Corporate Affairs, (902) 450-1588, ir@medmira.com
Andrea Young, Corporate Communications, (902) 450-1588, media@medmira.com
Source: MedMira Inc.
...an der prod.- pal. scheints MIR eher nicht zu liegen, denn die
wird inzwischen weltweit vertrieben, wobei natürlich solch aufbau
auch enorme kosten verursacht. hier wirds drauf ankommen innovative
lösungen zu finden.......und umzusetzen - denke, daß hats management inzwischen verstanden!!!!
akt. kurs- niv. scheint MIR für ´risikofreudige´ anleger
chancenreich
MedMira Strengthens US Patent Protection with New Filings and Continued Examination
Tuesday October 21, 9:15 am ET
HALIFAX, Oct. 21 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR, NASDAQ: MMIRF), a developer and marketer of rapid diagnostics, announced today that it is broadening its US patent portfolio with new filings related to the Company's rapid flow-through technology, the core innovation behind its rapid diagnostics. In order to strengthen its overall IP position, the Company has also filed for continued examination on its original US patent application that was allowed in July 2008.
ADVERTISEMENT
"We believe that our technology is one of our Company's most valuable assets and as such we are taking further steps to strengthen the IP around it, as we move forward with licensing and partnership opportunities. Additional IP was identified during our review and analysis of our rapid flow-through technology and we are now working with our external team to prepare and file patent applications to protect it," said Dr. Neeraj Vats, VP of Technology & Intellectual Property, MedMira Inc. "We will also be filing a Request for Continued Examination in order to strengthen our original US patent application, which received a Notice of Allowance from the USPTO earlier this year."
About MedMira
MedMira is a leading developer and manufacturer of flow-through rapid diagnostics. The company's tests provide hospitals, labs, clinics and individuals with reliable, rapid diagnosis for diseases such as HIV and hepatitis C in just three minutes. The company's tests are sold under the Reveal(R), MiraWell(R), MiraCare(TM) and Multiplo(TM) brands in global markets. MedMira's rapid HIV test is the only one in the world to achieve regulatory approvals in Canada, the United States, China and the European Union. MedMira's corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada. For more information visit MedMira's website at www.medmira.com.
This news release contains forward-looking statements, which involve risk and uncertainties and reflect the company's current expectation regarding future events. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this statement.
For further information
Dr. James Smith, Investor Relations & Corporate Affairs, (902) 450-1588, ir@medmira.com
Andrea Young, Corporate Communications, (902) 450-1588, media@medmira.com
Source: MedMira Inc.
...an der prod.- pal. scheints MIR eher nicht zu liegen, denn die
wird inzwischen weltweit vertrieben, wobei natürlich solch aufbau
auch enorme kosten verursacht. hier wirds drauf ankommen innovative
lösungen zu finden.......und umzusetzen - denke, daß hats management inzwischen verstanden!!!!
akt. kurs- niv. scheint MIR für ´risikofreudige´ anleger
chancenreich
.....und nicht zuletzt die phantasie eines CHANGE to OBAMA
sollte MIR ´nicht schaden´....IMO !!!
dazu auch mal ein beitrag ausm SH- board........
However, what I take away from the prospect of an Obama administration is that it can only be more positive for Medmira, or at least raising the profile of the type of solution and product that Medmira or like companies offers.
The US has been in debt for yeeeears now, but that doesn't stop them from having to retain their preminence as the global superpower and "moral" authority. Whether it's a title that's deserving is debatable but it is not in the American way to concede their rightful place. So, they will simply go into more debt if they need to to retain this crown.
What's another 10, 50, or 100 million dollar pledge when you already owe 11 trillion, and at least it's for a morally respectable cause than to bail out or finance wall-street crooks and dealers (who will get their share anyway through backdoor deals, regardless.)
Bottom line: the Obama factor can only help Medmira (or like-minded competitors).
smts
sollte MIR ´nicht schaden´....IMO !!!
dazu auch mal ein beitrag ausm SH- board........
However, what I take away from the prospect of an Obama administration is that it can only be more positive for Medmira, or at least raising the profile of the type of solution and product that Medmira or like companies offers.
The US has been in debt for yeeeears now, but that doesn't stop them from having to retain their preminence as the global superpower and "moral" authority. Whether it's a title that's deserving is debatable but it is not in the American way to concede their rightful place. So, they will simply go into more debt if they need to to retain this crown.
What's another 10, 50, or 100 million dollar pledge when you already owe 11 trillion, and at least it's for a morally respectable cause than to bail out or finance wall-street crooks and dealers (who will get their share anyway through backdoor deals, regardless.)
Bottom line: the Obama factor can only help Medmira (or like-minded competitors).
smts
....dafür, daß es die letzten tage kräftige abschläge an
den weltbörsen gab, schägt sich MIR erfreulich stabil - evtl.
meeeehr als ein ´hoffnungsschimmer´ ?!?!?!
HIV/AIDS Testing Market to Exceed $3.9 Billion by 2015, According to New Report by Global Industry Analysts, Inc.
Revolutionarydevelopments in the field of HIV disease monitoring and management havehad its direct impact on HIV testing market. The report forecastsworldwide HIV/AIDS Testing market to exceed $3.9 billion by 2015.
San Jose, California (PRWEB)October 23, 2008 -- Earlier considered a life threatening disease,HIV/AIDS has now emerged as a persistent condition that necessitatesefficient disease management. Such a change has encouraged people toincreasingly adopt HIV testing procedures, though the trend ispronounced in developed countries, and is gaining momentum indeveloping nations. Revolutionary changes in HIV disease monitoring andmanagement have had a significant influence on the HIV testing market.New disease-progression study techniques such as genotyping andphenotyping, and advancements in viral load monitoring tests havesignificantly improved therapies offered to HIV/AIDS infectedindividuals.
United States and Europe together accounted for over 60% share of the worldwide HIV/AIDS Testing marketin 2008, as stated in a recent report published by Global IndustryAnalysts, Inc. The relatively saturated markets in developed regions ofthe world are expected to be driven by enhanced emphasis on reducinginfection rates. Asia-Pacific is projected to witness the fastestgrowth over the analysis period. Africa, China, and India accountingfor about 90% of world HIV population, offer enormous potential formakers of HIV/AIDS Testing products. HIV/AIDS Screening Tests marketis projected to generate US$1.3 billion revenues by the year 2010.Growth in the monitoring market is highly dependent on success of HIVtherapies. Development of new products is likely to bring about furtherfragmentation of the market. HIV/AIDS Monitoring Test marketis projected to reach US$1.7 billion by 2015. The market isparticularly driven by the rising instances of drug resistance andincreasing number of genotyping tests. US and Europe account for about75% of the market size. This is partly due to affordability andaccessibility of these expensive tests in the regions.
HIV/AIDS Testing: A Global Strategic Business Report
United States HIV/AIDS Testing market is one of the highly developed and regulated markets in the world. HIV/AIDS confirmatory tests marketin the region is projected to reach US$32 million by 2015. With diseasemanagement taking precedence, new product introductions are likely tobecome the mainstay of many companies. Developments in monitoringmarkets along with HIV therapies, and development of molecular testingand probe technologies in Europe, are likely to have the highestpositive impact in HIV testing market in the long run. In Europe,France, Germany, Italy, and the United Kingdom command more than 65% ofthe European market.
Rapid test kits are likely to attract large customers as they claim tooffer instant results. Several producers are focused on developingrapid HIV test kit that produce results in less time and are solelyaimed at diagnosis. When compared with the popular enzyme-linkedimmunosorbent assay (ELISA) testing kits present in the market, rapidtest kits take much lesser time to detect, do not require anyspecialized equipment and are also less complicated. A key trendnoticed in the rapid testing market is combined HIV testing built onmultiple sampling modalities.
Blood Screening has emerged as a growing market for nucleic acidbased tests. This is mainly attributable to mandatory testing for blooddonations initiated by countries such as the United States for HIV-1and HCV.
Key players in world HIV/AIDS testing market with significant presenceinclude Abbott Laboratories Inc., Adaltis Inc., Siemens HealthcareDiagnostics Inc., Biomérieux SA, Bio-Rad Laboratories Inc., CalypteBiomedical Corporation, Celera Group, Gen-Probe Inc., Innogenetics NV,MedMira Laboratories, Inc., Medical Services International Inc.,OraSure Technologies Inc., Ortho-Clinical Diagnostics Inc., and RocheDiagnostics. In the rapid testing market, key participants compriseOrasure, Trinity Biotech, Calypte Biomedical Corporation, MedicalServices International Inc., and MedMira. OraSure Technologies, Inc.leads the market for oral fluid diagnostics worldwide.
The report titled "HIV/AIDS Testing: A Global Strategic BusinessReport" published by Global Industry Analysts, Inc., covers majormarket dynamics, trends, issues, and competition pertaining to themarket on a global as well as regional level. The report enumeratesrecent product innovations and launches, developments, mergers,acquisitions and other strategic industry activities. Analysis ispresented for established and emerging markets including United States,Japan, France, Germany, United Kingdom, Italy, Spain, Asia-Pacific,Latin America, and rest of World. The report focuses on variousregional statistics and growth drivers including development of rapidHIV test kits, rising awareness amongst the general population, andmeasures undertaken to reduce rate of HIV infection. The study examinesthe regulatory environment governing HIV/AIDS testing market across theworld. The report analyzes volume sales across two principal productsegments, namely HIV/AIDS Screening Tests, HIV/AIDS Confirmatory Tests.Revenues are analyzed across three segments, namely HIV/AIDS ScreeningTests, HIV/AIDS Confirmatory Tests, and HIV/AIDS Monitoring Tests.Analytics are provided for the period 2000-2015.
For more details of this research report, please visit http://www.strategyr.com/HIV_AIDS_Testing_Market_Report.asp" target="_blank" rel="nofollow ugc noopener">http://www.strategyr.com/HIV_AIDS_Testing_Market_Report.asp
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA)is a reputed publisher of off-the-shelf market research. Founded in1987, the company is globally recognized as one of the world's largestmarket research publishers. The company employs over 700 peopleworldwide and publishes more than 880 full-scale research reports eachyear. Additionally, the company also offers a range of over 60,000smaller research products including company reports, market trendreports, and industry reports encompassing all major industriesworldwide.
Global Industry Analysts, Inc.
Telephone 408-528-9966
Fax 408-528-9977
Email press@StrategyR.com
Web Site http://www.strategyr.com/
http://www.prweb.com/releases/HIV_AIDS_testing/screening_mon…
Time Ex Price Change Volume Buyer Seller Markers
13:06:53 V 0.10 +0.02 3,000 2 RBC 1 Anonymous K
13:06:35 V 0.10 +0.02 10,000 2 RBC 7 TD Sec K
13:06:35 V 0.10 +0.02 3,000 2 RBC 9 BMO Nesbitt K
13:06:22 V 0.10 +0.02 17,000 2 RBC 2 RBC K
13:06:22 V 0.10 +0.02 5,000 2 RBC 9 BMO Nesbitt K
13:06:22 V 0.10 +0.02 3,000 2 RBC 7 TD Sec K
13:06:22 V 0.10 +0.02 15,000 2 RBC 7 TD Sec K
13:04:57 V 0.095 +0.015 10,000 2 RBC 7 TD Sec K
13:04:41 V 0.095 +0.015 18,000 2 RBC 7 TD Sec K
13:03:15 V 0.09 +0.01 10,000 2 RBC 7 TD Sec K
........wow, es ruckt in CAN
Antwort auf Beitrag Nr.: 35.678.118 von hbg55 am 23.10.08 19:24:09
.....RBC scheinen die jüngsten entwicklungen zu gefallen - wie
sonst zu erklären, daß die kräftig einsammeln !!!!
.....RBC scheinen die jüngsten entwicklungen zu gefallen - wie
sonst zu erklären, daß die kräftig einsammeln !!!!
Antwort auf Beitrag Nr.: 35.678.251 von hbg55 am 23.10.08 19:34:05
...oder läßt ein BIG PLAYER einsammeln......ob
der lukrativen patente
anyhow......grad bei akt. marktlage scheint mir ein
invest hier aus verschiedenen gründen angebracht
...oder läßt ein BIG PLAYER einsammeln......ob
der lukrativen patente
anyhow......grad bei akt. marktlage scheint mir ein
invest hier aus verschiedenen gründen angebracht
....soooo......nach der hektischen eröffnung findet MIR
wieder tritt und klettert zurück gen gestriges niveau
RT...cad 0,085
Time Ex Price Change Volume Buyer Seller Markers
14:13:20 V 0.085 -0.005 500 2 RBC 7 TD Sec E
13:43:09 V 0.09 -0.005 3,000 1 Anonymous 7 TD Sec K
13:24:48 V 0.08 -0.015 3,000 7 TD Sec 19 Desjardins K
13:24:48 V 0.085 -0.01 2,000 7 TD Sec 19 Desjardins K
13:13:13 V 0.085 -0.01 3,000 7 TD Sec 7 TD Sec K
12:34:16 V 0.085 -0.01 5,000 85 Scotia 7 TD Sec K
12:32:51 V 0.085 -0.01 5,000 85 Scotia 7 TD Sec K
12:31:02 V 0.085 -0.01 7,000 85 Scotia 7 TD Sec K
12:28:26 V 0.085 -0.01 10,000 85 Scotia 7 TD Sec K
12:28:26 V 0.085 -0.01 3,000 85 Scotia 7 TD Sec K
14:13:20 V 0.085 -0.005 500 2 RBC 7 TD Sec E
13:43:09 V 0.09 -0.005 3,000 1 Anonymous 7 TD Sec K
13:24:48 V 0.08 -0.015 3,000 7 TD Sec 19 Desjardins K
13:24:48 V 0.085 -0.01 2,000 7 TD Sec 19 Desjardins K
13:13:13 V 0.085 -0.01 3,000 7 TD Sec 7 TD Sec K
12:34:16 V 0.085 -0.01 5,000 85 Scotia 7 TD Sec K
12:32:51 V 0.085 -0.01 5,000 85 Scotia 7 TD Sec K
12:31:02 V 0.085 -0.01 7,000 85 Scotia 7 TD Sec K
12:28:26 V 0.085 -0.01 10,000 85 Scotia 7 TD Sec K
12:28:26 V 0.085 -0.01 3,000 85 Scotia 7 TD Sec K
Antwort auf Beitrag Nr.: 35.690.357 von hbg55 am 24.10.08 16:54:27
....gibt nicht viele werte, die die vergangene woche mit
ÜBER 10 % im PLUS geschlossen haben - wie gehts weiter
hier ????
....ich bleib optimistisch !!!
....gibt nicht viele werte, die die vergangene woche mit
ÜBER 10 % im PLUS geschlossen haben - wie gehts weiter
hier ????
....ich bleib optimistisch !!!
Time Ex Price Change Volume Buyer Seller Markers
12:30:24 V 0.095 +0.005 4,000 5 Penson 7 TD Sec K
12:30:24 V 0.095 +0.005 5,000 5 Penson 19 Desjardins K
12:29:45 V 0.085 -0.005 6,000 5 Penson 80 National Bank K
11:58:39 V 0.085 -0.005 14,000 2 RBC 80 National Bank K
11:56:27 V 0.085 -0.005 6,000 2 RBC 7 TD Sec K
10:44:41 V 0.08 -0.01 5,000 7 TD Sec 7 TD Sec K
09:47:01 V 0.085 -0.005 5,000 19 Desjardins 7 TD Sec KL
12:30:24 V 0.095 +0.005 4,000 5 Penson 7 TD Sec K
12:30:24 V 0.095 +0.005 5,000 5 Penson 19 Desjardins K
12:29:45 V 0.085 -0.005 6,000 5 Penson 80 National Bank K
11:58:39 V 0.085 -0.005 14,000 2 RBC 80 National Bank K
11:56:27 V 0.085 -0.005 6,000 2 RBC 7 TD Sec K
10:44:41 V 0.08 -0.01 5,000 7 TD Sec 7 TD Sec K
09:47:01 V 0.085 -0.005 5,000 19 Desjardins 7 TD Sec KL
Time Ex Price Change Volume Buyer Seller Markers
12:23:56 V 0.115 +0.015 200 7 TD Sec 95 Wolverton E
12:23:56 V 0.095 +0.015 1,000 7 TD Sec 7 TD Sec K
11:30:30 V 0.09 +0.01 11,000 79 CIBC 7 TD Sec K
11:30:30 V 0.09 +0.01 14,000 79 CIBC 7 TD Sec K
11:29:38 V 0.085 +0.005 4,000 1 Anonymous 124 Questrade K
11:29:38 V 0.085 +0.005 1,000 79 CIBC 124 Questrade K
11:10:43 V 0.09 +0.01 1,000 79 CIBC 7 TD Sec K
11:00:14 V 0.09 +0.01 4,000 79 CIBC 7 TD Sec K
10:50:27 V 0.09 +0.01 6,000 79 CIBC 7 TD Sec K
10:48:52 V 0.095 +0.015 5,000 7 TD Sec 7 TD Sec K
int. an MIR nimmt weiter zu
12:23:56 V 0.115 +0.015 200 7 TD Sec 95 Wolverton E
12:23:56 V 0.095 +0.015 1,000 7 TD Sec 7 TD Sec K
11:30:30 V 0.09 +0.01 11,000 79 CIBC 7 TD Sec K
11:30:30 V 0.09 +0.01 14,000 79 CIBC 7 TD Sec K
11:29:38 V 0.085 +0.005 4,000 1 Anonymous 124 Questrade K
11:29:38 V 0.085 +0.005 1,000 79 CIBC 124 Questrade K
11:10:43 V 0.09 +0.01 1,000 79 CIBC 7 TD Sec K
11:00:14 V 0.09 +0.01 4,000 79 CIBC 7 TD Sec K
10:50:27 V 0.09 +0.01 6,000 79 CIBC 7 TD Sec K
10:48:52 V 0.095 +0.015 5,000 7 TD Sec 7 TD Sec K
int. an MIR nimmt weiter zu
Antwort auf Beitrag Nr.: 35.750.570 von hbg55 am 29.10.08 18:01:53
...gut vorstellbar, daß es an dieser meldung liegt......
MedMira 1.13 million shares for debt
2008-10-28 16:22 ET - Shares for Debt
The TSX Venture Exchange has accepted for filing the company's proposal to issue 1,132,165 shares to settle outstanding debt for $104,650.
...gut vorstellbar, daß es an dieser meldung liegt......
MedMira 1.13 million shares for debt
2008-10-28 16:22 ET - Shares for Debt
The TSX Venture Exchange has accepted for filing the company's proposal to issue 1,132,165 shares to settle outstanding debt for $104,650.
....wow, schon 1 mio. gehandelt mit PLUS 30 % - was
geht da heute UPPP
Antwort auf Beitrag Nr.: 35.856.030 von hbg55 am 06.11.08 16:43:02
...denke MIR sollte auch das zeug haben sich zu einem
OBAMA- winner entwickeln zu können - ist doch das
HIV- thema weit oben auf seiner agenda angesiedelt !!!!
dazu mal hier reinschauen........
http://www.youtube.com/watch?v=4f-nYgXceA8
...denke MIR sollte auch das zeug haben sich zu einem
OBAMA- winner entwickeln zu können - ist doch das
HIV- thema weit oben auf seiner agenda angesiedelt !!!!
dazu mal hier reinschauen........
http://www.youtube.com/watch?v=4f-nYgXceA8
Antwort auf Beitrag Nr.: 35.858.756 von hbg55 am 06.11.08 20:00:01
...oder haben gestrige sprünge etwas mit nachfolg.
bericht zu tun..........
Biovail looking at potential acquisitions as Q3 profit slides 27 per cent
Eric Shackleton, The Canadian Press
November 6, 2008 - 2:12 p.m.
TORONTO - Biovail Corp. (TSX:BVF) is looking at opportunities to expand through acquisitions, and believes its balance sheet is strong enough to support this strategy despite a 27 per cent drop in third-quarter earnings.
Canada's largest publicly traded drugmaker is "actively evaluating numerous products as in-licensing or acquisition targets," CEO Bill Wells told a conference call Thursday after Biovail reported three-month net income of $48.4 million, down from $65.9 million a year earlier.
Revenue declined to $181.1 million from $188.9 million. Earnings per share were 31 cents, down from 41 cents a year earlier.
All of the acquisition prospects being considered have "products in the marketplace" with the potential of producing earnings within 12 months of acquisition, said Wells.
All of the acquisition prospects being considered have "products in the marketplace" with the potential of producing earnings within 12 months of acquisition, said Wells.
However, he said he could not predict if or when an acquisition might occur.
"Our objective is to build a robust portfolio with a balance of near, mid and long term programs," said Wells. "We will be diligent and prudent with our investment decisions."
Wells noted that Biovail has acquired its first specialty drug for central nervous system ailments, a key part of its new strategic focus, and expects to launch Xenazine, for Huntington's chorea, in the United States this year.
"Our business development activities are at full speed," he stated.
"The recent financial market turmoil is likely to create opportunities in terms of business development for companies like Biovail with a strong balance sheet and cash flows."
Peggy Mulligan, Biovail's chief financial officer, noted that the company held cash and equivalents of $219 million and marketable securities of $23 million at the end of the quarter. It remains free of long-term debt, she added, and it has no outstanding balances against a $250-million credit line.
"That facility remains an attractive source of funds should our acquisition strategy require short-term borrowing," Mulligan said.
The latest quarter was pulled down by one-time items totalling five cents per share: $7.6 million in restructuing costs, $2 million in legal settlements, $728,000 to fight off a proxy battle mounted by former CEO Eugene Melnyk, and a $1.2-million writedown of investments
Wells said the company's efforts to reduce costs and boost efficiencies through restructuring are making good progress.
Wells said the company's efforts to reduce costs and boost efficiencies through restructuring are making good progress.
"We are on track to complete the closure of our Puerto Rico manufacturing facilities within approximately 16 months. The shutdown of our research and development site in Dublin, Ireland, is essentially complete."
Biovail expects to sell the Dublin site within the next 12 months, he said.
However, in Puerto Rico, where there are many pharmaceutical plants on the market, "it is less likely that we will be successful in that time period."
However, in Puerto Rico, where there are many pharmaceutical plants on the market, "it is less likely that we will be successful in that time period."
About 300 employees - one-fifth of the company's workforce - will be let go, said Wells.
The restructuring effort, aiming at annual savings of $30 million to $40 million, is not expected to reduce revenues.
Wells said Biovail has realized $22 million of its targeted $100 million in proceeds from the sale of non-core assets.
It also has revamped its senior management, making Biovail "a substantially new company" as it struggles to reposition itself in the pharmaceutical industry.
On Thursday, Biovail announced the appointment of Dr. Christian Fibiger to the newly created role of chief scientific officer, based in Barbados and overseeing the development of the product pipeline.
Fibiger was most recently chief scientific officer of MedGenesis Therapeutix of Victoria, and previously was vice-president in charge of neuroscience at Amgen Inc.
Biovail's board maintained the quarterly dividend of 37.5 cents per share, which yields 14 per cent at Thursday afternoon's stock price of $10.68, off a penny on the TSX session.
The stock is down from almost $18 a year ago, but up from an October low of $7.84.
Biovail's impending U.S. launch of Zenazine follows the September acquisition of Prestwick Pharmaceuticals, a privately held U.S. company with licensing rights to tetrabenazine tablets, known as Xenazine in the U.S. and Nitoman in Canada.
Biovail's impending U.S. launch of Zenazine follows the September acquisition of Prestwick Pharmaceuticals, a privately held U.S. company with licensing rights to tetrabenazine tablets, known as Xenazine in the U.S. and Nitoman in Canada.
The U.S. Food and Drug Administration has granted the drug orphan status, which provides seven years of American market exclusivity.
......da könnte MIRs product-pipeline eine wunderbare
ergänzung darstellen....IMO !!!!
...oder haben gestrige sprünge etwas mit nachfolg.
bericht zu tun..........
Biovail looking at potential acquisitions as Q3 profit slides 27 per cent
Eric Shackleton, The Canadian Press
November 6, 2008 - 2:12 p.m.
TORONTO - Biovail Corp. (TSX:BVF) is looking at opportunities to expand through acquisitions, and believes its balance sheet is strong enough to support this strategy despite a 27 per cent drop in third-quarter earnings.
Canada's largest publicly traded drugmaker is "actively evaluating numerous products as in-licensing or acquisition targets," CEO Bill Wells told a conference call Thursday after Biovail reported three-month net income of $48.4 million, down from $65.9 million a year earlier.
Revenue declined to $181.1 million from $188.9 million. Earnings per share were 31 cents, down from 41 cents a year earlier.
All of the acquisition prospects being considered have "products in the marketplace" with the potential of producing earnings within 12 months of acquisition, said Wells.
All of the acquisition prospects being considered have "products in the marketplace" with the potential of producing earnings within 12 months of acquisition, said Wells.
However, he said he could not predict if or when an acquisition might occur.
"Our objective is to build a robust portfolio with a balance of near, mid and long term programs," said Wells. "We will be diligent and prudent with our investment decisions."
Wells noted that Biovail has acquired its first specialty drug for central nervous system ailments, a key part of its new strategic focus, and expects to launch Xenazine, for Huntington's chorea, in the United States this year.
"Our business development activities are at full speed," he stated.
"The recent financial market turmoil is likely to create opportunities in terms of business development for companies like Biovail with a strong balance sheet and cash flows."
Peggy Mulligan, Biovail's chief financial officer, noted that the company held cash and equivalents of $219 million and marketable securities of $23 million at the end of the quarter. It remains free of long-term debt, she added, and it has no outstanding balances against a $250-million credit line.
"That facility remains an attractive source of funds should our acquisition strategy require short-term borrowing," Mulligan said.
The latest quarter was pulled down by one-time items totalling five cents per share: $7.6 million in restructuing costs, $2 million in legal settlements, $728,000 to fight off a proxy battle mounted by former CEO Eugene Melnyk, and a $1.2-million writedown of investments
Wells said the company's efforts to reduce costs and boost efficiencies through restructuring are making good progress.
Wells said the company's efforts to reduce costs and boost efficiencies through restructuring are making good progress.
"We are on track to complete the closure of our Puerto Rico manufacturing facilities within approximately 16 months. The shutdown of our research and development site in Dublin, Ireland, is essentially complete."
Biovail expects to sell the Dublin site within the next 12 months, he said.
However, in Puerto Rico, where there are many pharmaceutical plants on the market, "it is less likely that we will be successful in that time period."
However, in Puerto Rico, where there are many pharmaceutical plants on the market, "it is less likely that we will be successful in that time period."
About 300 employees - one-fifth of the company's workforce - will be let go, said Wells.
The restructuring effort, aiming at annual savings of $30 million to $40 million, is not expected to reduce revenues.
Wells said Biovail has realized $22 million of its targeted $100 million in proceeds from the sale of non-core assets.
It also has revamped its senior management, making Biovail "a substantially new company" as it struggles to reposition itself in the pharmaceutical industry.
On Thursday, Biovail announced the appointment of Dr. Christian Fibiger to the newly created role of chief scientific officer, based in Barbados and overseeing the development of the product pipeline.
Fibiger was most recently chief scientific officer of MedGenesis Therapeutix of Victoria, and previously was vice-president in charge of neuroscience at Amgen Inc.
Biovail's board maintained the quarterly dividend of 37.5 cents per share, which yields 14 per cent at Thursday afternoon's stock price of $10.68, off a penny on the TSX session.
The stock is down from almost $18 a year ago, but up from an October low of $7.84.
Biovail's impending U.S. launch of Zenazine follows the September acquisition of Prestwick Pharmaceuticals, a privately held U.S. company with licensing rights to tetrabenazine tablets, known as Xenazine in the U.S. and Nitoman in Canada.
Biovail's impending U.S. launch of Zenazine follows the September acquisition of Prestwick Pharmaceuticals, a privately held U.S. company with licensing rights to tetrabenazine tablets, known as Xenazine in the U.S. and Nitoman in Canada.
The U.S. Food and Drug Administration has granted the drug orphan status, which provides seven years of American market exclusivity.
......da könnte MIRs product-pipeline eine wunderbare
ergänzung darstellen....IMO !!!!
RT...cad 0,10
Time Ex Price Change Volume Buyer Seller Markers
11:50:05 V 0.10 +0.005 10,000 9 BMO Nesbitt 89 Raymond James K
11:31:06 V 0.095 - 15,000 85 Scotia 7 TD Sec K
10:10:43 V 0.095 - 10,000 85 Scotia 19 Desjardins K
10:10:43 V 0.095 - 2,000 85 Scotia 80 National Bank K
10:06:25 V 0.095 - 5,000 7 TD Sec 80 National Bank K
09:58:54 V 0.095 - 13,000 2 RBC 80 National Bank K
09:58:54 V 0.095 - 10,000 2 RBC 7 TD Sec K
09:58:54 V 0.095 - 7,000 2 RBC 88 E-TRADE K
09:46:55 V 0.095 - 10,000 85 Scotia 88 E-TRADE K
09:46:49 V 0.095 - 28,000 7 TD Sec 88 E-TRADE K
11:50:05 V 0.10 +0.005 10,000 9 BMO Nesbitt 89 Raymond James K
11:31:06 V 0.095 - 15,000 85 Scotia 7 TD Sec K
10:10:43 V 0.095 - 10,000 85 Scotia 19 Desjardins K
10:10:43 V 0.095 - 2,000 85 Scotia 80 National Bank K
10:06:25 V 0.095 - 5,000 7 TD Sec 80 National Bank K
09:58:54 V 0.095 - 13,000 2 RBC 80 National Bank K
09:58:54 V 0.095 - 10,000 2 RBC 7 TD Sec K
09:58:54 V 0.095 - 7,000 2 RBC 88 E-TRADE K
09:46:55 V 0.095 - 10,000 85 Scotia 88 E-TRADE K
09:46:49 V 0.095 - 28,000 7 TD Sec 88 E-TRADE K
MedMira and Swiss Partner Vitest Sign Private Label Agreement for Africa
HALIFAX, March 10 /CNW/
- MedMira Inc., ("MedMira") (TSX Venture: MIR, NASDAQ: MMIRF), a developer and marketer of rapid diagnostic technology and solutions, announced today that it is has established a private label partnership with Vitest AG (Vitest). Vitest, an established private label partner of MedMira, plans to market and sell MedMira rapid HIV tests in Africa under the Vitest brand. This partnership will increase the availability of quality rapid HIV tests in Africa, a market where an urgent need for testing exists, with an estimated 22 million people infected with HIV and nearly 2 million newly infected each year. (www.unaids.org)
"MedMira and Vitest are coming together to respond to a growing need and to deliver, what we believe will be the highest quality and most superior rapid HIV test available in the African market," said Dr. Jörg-Michael Hollidt, CEO, Vitest AG. "The collaboration between our two companies enables us to deliver quickly and efficiently a high quality, world class diagnostic solution with the flexibility to meet the varied needs of public health and private company testing programs in Africa."
The partnership enables each company to bring their core skills and focus together to achieve success in complex and highly competitive developing markets such as Africa. Under the terms of the agreement, MedMira will manufacture its complete line of rapid diagnostics, which includes HIV, hepatitis and multiple tests built on the Company's patented and award-winning rapid flow-through technology platform, for Vitest to market and sell through various channels in Africa, including public health tenders and private company-sponsored programs.
"We know that Africa is where one of the greatest testing needs exists and we now have the right partner in Vitest and the infrastructure in place to serve this market profitably," said Hermes Chan, CEO, MedMira Inc. "Our newly outsourced manufacturing capabilities will enable us to meet the volume and pricing demands of this highly competitive, price-driven market. We look forward to working closely with Vitest to establish a firm position in Africa for the MedMira/Vitest products."
Chan continued, "By integrating our efforts we can successfully meet the pricing and volume requirements that the Africa market demands. The focus of our partnership will be to deliver high volumes of quality rapid HIV tests at market-driven prices."
About Vitest
Vitest AG is a privately held company based in Wollerau, Switzerland (www.vitest.ch) with a corporate subsidiary in Germany (Vitest GmbH). Vitest is manufacturer of medical rapid tests and known well for their high quality products. The company provides doctors offices, clinics and government institutions with innovative rapid tests. With the introduction of Vitest HIV to the German market, Vitest takes the lead in the latest AIDS prevention movement to reduce the number of new HIV infections in Germany, by making better diagnostics more widely available. For more information about Vitest Europe, please contact Christiane Ewel, Head of Marketing and Sales Europe (ch.ewel@vitest.de), Vitest GmbH, D -16761 Hennigsdorf, Neuendorfstrasse 24b, Tel. +49 3302 202 7100, Fax. +49 3302 202 7199 or for Vitest International, please contact Nicholas Dellaportas (n.dellaportas@vitest.ch), Director of Business Development and Sales, Vitest AG, UK - 33 Thames Point, The Boulevard, Imperial Wharf, London, SW6 2 SX, +44 77111 826550, Fax. +4420 7371 5110.
About MedMira
MedMira is a leading developer and manufacturer of flow-through rapid diagnostics. The company's tests provide hospitals, labs, clinics and individuals with reliable, rapid diagnosis for diseases such as HIV and hepatitis C in just three minutes. The company's tests are sold under the Reveal(R), MiraWell(R), MiraCare(TM) and Multiplo(TM) brands in global markets. MedMira's rapid HIV test is the only one in the world to achieve regulatory approvals in Canada, the United States, China and the European Union. MedMira's corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada. For more information visit MedMira's website at www.medmira.com.
This news release contains forward-looking statements, which involve risk and uncertainties and reflect the company's current expectation regarding future events. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this statement.
%SEDAR: 00013053E
Source: Canada NewsWire (March 10, 2009 - 8:30 AM EDT)
News by QuoteMedia
...........mit obiger news macht MIR nen kräftigen satz
gen norden
RT...cad 0,08
...mal schauen, obs sogar übern widerstand bei 0,08 geht
Antwort auf Beitrag Nr.: 36.737.764 von hbg55 am 10.03.09 15:32:39
....heutige RAKETE hat ihren ursprung in nachfolg. news......
MedMira sells first products in Indonesian market
2009-04-21 09:08 ET - News Release
Mr. Hermes Chan reports
MEDMIRA AND AHD ACHIEVE FIRST SALES WIN IN INDONESIA AS A RESULT OF SOUTH EAST ASIA MARKET EXPANSION
MedMira Inc. and United States-based sales and marketing partner American Health Diagnostics LLC (AHD)'s Southeast Asia market expansion initiatives have resulted in product sales in Indonesia. As announced in August, 2008, MedMira and AHD are working together to break in to this developing market and sell at least one million rapid HIV tests in the Southeast Asia region over the next year.
Local distributors Lauw Management USA and PT Sehat Selaras Sejahtera, along with MedMira and AHD, pursued and received regulatory approval in Indonesia for MedMira's MiraWell rapid HIV test (MiraWell HIV). In addition to regulatory approval, the sales and marketing registrations required to sell the product in this market have also been completed.
"We have converted our Southeast Asia market expansion into concrete sales opportunities in Indonesia. Working with our partners, AHD, Lauw Management USA and PT Sehat Selaras Sejahtera, we were able to move through the evaluation and regulatory process smoothly in order to realize our first sales in the region," said Hermes Chan, president and chief executive officer, MedMira. "This is the first in a series of initiatives included in our market development plan for the region. Working with our strategic partners in Southeast Asia we will sell our competitively priced, quality diagnostics to other countries in the region."
....heutige RAKETE hat ihren ursprung in nachfolg. news......
MedMira sells first products in Indonesian market
2009-04-21 09:08 ET - News Release
Mr. Hermes Chan reports
MEDMIRA AND AHD ACHIEVE FIRST SALES WIN IN INDONESIA AS A RESULT OF SOUTH EAST ASIA MARKET EXPANSION
MedMira Inc. and United States-based sales and marketing partner American Health Diagnostics LLC (AHD)'s Southeast Asia market expansion initiatives have resulted in product sales in Indonesia. As announced in August, 2008, MedMira and AHD are working together to break in to this developing market and sell at least one million rapid HIV tests in the Southeast Asia region over the next year.
Local distributors Lauw Management USA and PT Sehat Selaras Sejahtera, along with MedMira and AHD, pursued and received regulatory approval in Indonesia for MedMira's MiraWell rapid HIV test (MiraWell HIV). In addition to regulatory approval, the sales and marketing registrations required to sell the product in this market have also been completed.
"We have converted our Southeast Asia market expansion into concrete sales opportunities in Indonesia. Working with our partners, AHD, Lauw Management USA and PT Sehat Selaras Sejahtera, we were able to move through the evaluation and regulatory process smoothly in order to realize our first sales in the region," said Hermes Chan, president and chief executive officer, MedMira. "This is the first in a series of initiatives included in our market development plan for the region. Working with our strategic partners in Southeast Asia we will sell our competitively priced, quality diagnostics to other countries in the region."
...mit RIESEN- vol. haben wir binnen kürzester zeit schon
über 6,5 mio. vol.......mit akt. TH von cad 0,115......
Time Ex Price Change Volume Buyer Seller Markers
10:42:14 V 0.105 +0.045 10,000 19 Desjardins 7 TD Sec K
10:41:55 V 0.11 +0.05 5,000 7 TD Sec 7 TD Sec K
10:41:46 V 0.11 +0.05 20,000 7 TD Sec 7 TD Sec K
10:41:45 V 0.11 +0.05 10,000 2 RBC 7 TD Sec K
10:41:43 V 0.105 +0.045 10,000 19 Desjardins 79 CIBC K
10:41:38 V 0.11 +0.05 7,000 124 Questrade 80 National Bank K
10:41:38 V 0.11 +0.05 50,000 124 Questrade 80 National Bank K
10:41:32 V 0.115 +0.055 4,000 85 Scotia 33 Canaccord K
10:41:31 V 0.115 +0.055 25,000 85 Scotia 1 Anonymous K
10:41:31 V 0.115 +0.055 10,000 85 Scotia 7 TD Sec K
Antwort auf Beitrag Nr.: 37.010.764 von hbg55 am 21.04.09 17:00:00
...sahen schlussendlich REKORD- vol. von über 13mio gehandelter shares und verharrten nach volatilem handel an der widerstandsmarke
bei cad 0,10.........
Recent Trades - Last 10
Time Ex Price Change Volume Buyer Seller Markers
15:59:37 V 0.075 +0.035 500 95 Wolverton 7 TD Sec E
15:59:37 V 0.095 +0.035 31,000 7 TD Sec 7 TD Sec K
15:59:37 V 0.095 +0.035 10,000 7 TD Sec 7 TD Sec K
15:59:37 V 0.095 +0.035 11,000 88 Scotia iTRADE 7 TD Sec K
15:59:37 V 0.095 +0.035 5,000 79 CIBC 7 TD Sec K
15:59:09 V 0.095 +0.035 10,000 7 TD Sec 7 TD Sec K
15:58:33 V 0.10 +0.04 30,000 7 TD Sec 7 TD Sec K
15:56:04 V 0.095 +0.035 10,000 7 TD Sec 7 TD Sec K
15:54:45 V 0.095 +0.035 10,000 7 TD Sec 7 TD Sec K
15:50:32 V 0.10 +0.04 20,000 19 Desjardins 19 Desjardins K
......bin gespannt, ob wir diesmal im stande sind diese barriere
zu überwinden
...sahen schlussendlich REKORD- vol. von über 13mio gehandelter shares und verharrten nach volatilem handel an der widerstandsmarke
bei cad 0,10.........
Recent Trades - Last 10
Time Ex Price Change Volume Buyer Seller Markers
15:59:37 V 0.075 +0.035 500 95 Wolverton 7 TD Sec E
15:59:37 V 0.095 +0.035 31,000 7 TD Sec 7 TD Sec K
15:59:37 V 0.095 +0.035 10,000 7 TD Sec 7 TD Sec K
15:59:37 V 0.095 +0.035 11,000 88 Scotia iTRADE 7 TD Sec K
15:59:37 V 0.095 +0.035 5,000 79 CIBC 7 TD Sec K
15:59:09 V 0.095 +0.035 10,000 7 TD Sec 7 TD Sec K
15:58:33 V 0.10 +0.04 30,000 7 TD Sec 7 TD Sec K
15:56:04 V 0.095 +0.035 10,000 7 TD Sec 7 TD Sec K
15:54:45 V 0.095 +0.035 10,000 7 TD Sec 7 TD Sec K
15:50:32 V 0.10 +0.04 20,000 19 Desjardins 19 Desjardins K
......bin gespannt, ob wir diesmal im stande sind diese barriere
zu überwinden
Antwort auf Beitrag Nr.: 37.014.518 von hbg55 am 22.04.09 08:46:29
....HEUTE warens immerhin noch 3 mio. vol., allerdings negativ
belastet, wie der umstand unterstreicht auf TT ausm handel zu
gehen...........
Recent Trades - Last 10
Time Ex Price Change Volume Buyer Seller Markers
15:59:41 V 0.075 -0.02 5,000 88 Scotia iTRADE 88 Scotia iTRADE K
15:59:41 V 0.075 -0.02 20,000 88 Scotia iTRADE 88 Scotia iTRADE K
15:58:45 V 0.075 -0.02 2,000 2 RBC 85 Scotia K
15:58:45 V 0.075 -0.02 10,000 19 Desjardins 85 Scotia K
15:57:24 V 0.08 -0.015 23,000 7 TD Sec 85 Scotia K
15:57:05 V 0.08 -0.015 65,000 7 TD Sec 85 Scotia K
15:54:18 V 0.08 -0.015 12,000 88 Scotia iTRADE 7 TD Sec K
15:53:36 V 0.08 -0.015 12,000 88 Scotia iTRADE 88 Scotia iTRADE K
15:52:28 V 0.08 -0.015 26,000 88 Scotia iTRADE 81 HSBC K
15:52:28 V 0.08 -0.015 14,000 1 Anonymous 81 HSBC K
....HEUTE warens immerhin noch 3 mio. vol., allerdings negativ
belastet, wie der umstand unterstreicht auf TT ausm handel zu
gehen...........
Recent Trades - Last 10
Time Ex Price Change Volume Buyer Seller Markers
15:59:41 V 0.075 -0.02 5,000 88 Scotia iTRADE 88 Scotia iTRADE K
15:59:41 V 0.075 -0.02 20,000 88 Scotia iTRADE 88 Scotia iTRADE K
15:58:45 V 0.075 -0.02 2,000 2 RBC 85 Scotia K
15:58:45 V 0.075 -0.02 10,000 19 Desjardins 85 Scotia K
15:57:24 V 0.08 -0.015 23,000 7 TD Sec 85 Scotia K
15:57:05 V 0.08 -0.015 65,000 7 TD Sec 85 Scotia K
15:54:18 V 0.08 -0.015 12,000 88 Scotia iTRADE 7 TD Sec K
15:53:36 V 0.08 -0.015 12,000 88 Scotia iTRADE 88 Scotia iTRADE K
15:52:28 V 0.08 -0.015 26,000 88 Scotia iTRADE 81 HSBC K
15:52:28 V 0.08 -0.015 14,000 1 Anonymous 81 HSBC K
Antwort auf Beitrag Nr.: 37.022.416 von hbg55 am 22.04.09 23:37:50
...lags an nachfolg. news.........
MedMira to draw down $75,000 from YA credit line
2009-04-22 16:12 ET - News Release
Ms. Andrea Young reports
MEDMIRA ANNOUNCES DRAW DOWN OF EQUITY LINE
MedMira Inc. has submitted a drawdown notice for $75,000 to YA Global Investments LP against its equity line of credit. MedMira is accessing this capital to support the development of its new strategic partnership program as well as global sales, marketing and business development initiatives. Under the terms negotiated in the equity line, YA Global will purchase common shares from MedMira at a price to be calculated based on 96.5 per cent of the daily volume weighted average price over a 10-day pricing period, beginning on April 22, 2009. The settlement date is May 6, 2009. The issuance of the MedMira common shares with respect to this drawdown is subject to the approval of the TSX Venture Exchange.
...lags an nachfolg. news.........
MedMira to draw down $75,000 from YA credit line
2009-04-22 16:12 ET - News Release
Ms. Andrea Young reports
MEDMIRA ANNOUNCES DRAW DOWN OF EQUITY LINE
MedMira Inc. has submitted a drawdown notice for $75,000 to YA Global Investments LP against its equity line of credit. MedMira is accessing this capital to support the development of its new strategic partnership program as well as global sales, marketing and business development initiatives. Under the terms negotiated in the equity line, YA Global will purchase common shares from MedMira at a price to be calculated based on 96.5 per cent of the daily volume weighted average price over a 10-day pricing period, beginning on April 22, 2009. The settlement date is May 6, 2009. The issuance of the MedMira common shares with respect to this drawdown is subject to the approval of the TSX Venture Exchange.
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| 0,00 | |
| -0,35 | |
| +1,08 | |
| +0,04 | |
| -0,02 | |
| -2,81 | |
| 0,00 | |
| +0,06 | |
| -0,72 | |
| -1,78 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 181 | ||
| 108 | ||
| 67 | ||
| 55 | ||
| 40 | ||
| 38 | ||
| 29 | ||
| 21 | ||
| 21 | ||
| 21 |
01.05.24 · IRW Press · Medmira |
01.05.24 · IRW Press · Medmira |
14.03.24 · IRW Press · Medmira |
05.02.24 · IRW Press · Medmira |
14.12.23 · Jochen Staiger · Abbott Laboratories |